GB202209285D0 - Dosage regimen for AXL inhibitor - Google Patents

Dosage regimen for AXL inhibitor

Info

Publication number
GB202209285D0
GB202209285D0 GBGB2209285.2A GB202209285A GB202209285D0 GB 202209285 D0 GB202209285 D0 GB 202209285D0 GB 202209285 A GB202209285 A GB 202209285A GB 202209285 D0 GB202209285 D0 GB 202209285D0
Authority
GB
United Kingdom
Prior art keywords
dosage regimen
axl inhibitor
axl
inhibitor
regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2209285.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BerGenBio ASA
Original Assignee
BerGenBio ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BerGenBio ASA filed Critical BerGenBio ASA
Priority to GBGB2209285.2A priority Critical patent/GB202209285D0/en
Publication of GB202209285D0 publication Critical patent/GB202209285D0/en
Priority to PCT/EP2023/067153 priority patent/WO2023247769A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
GBGB2209285.2A 2022-06-24 2022-06-24 Dosage regimen for AXL inhibitor Ceased GB202209285D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2209285.2A GB202209285D0 (en) 2022-06-24 2022-06-24 Dosage regimen for AXL inhibitor
PCT/EP2023/067153 WO2023247769A1 (en) 2022-06-24 2023-06-23 Dosage regimen for axl inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2209285.2A GB202209285D0 (en) 2022-06-24 2022-06-24 Dosage regimen for AXL inhibitor

Publications (1)

Publication Number Publication Date
GB202209285D0 true GB202209285D0 (en) 2022-08-10

Family

ID=82705298

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2209285.2A Ceased GB202209285D0 (en) 2022-06-24 2022-06-24 Dosage regimen for AXL inhibitor

Country Status (2)

Country Link
GB (1) GB202209285D0 (en)
WO (1) WO2023247769A1 (en)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884119B2 (en) 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
CA3052368A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
JP2008130120A (en) 2006-11-17 2008-06-05 Sharp Corp Optical pickup device
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
JP5546250B2 (en) 2006-12-29 2014-07-09 ライジェル ファーマシューティカルズ， インコーポレイテッド Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
EP2114954B1 (en) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2946305C (en) 2006-12-29 2019-09-17 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
JP5567837B2 (en) 2006-12-29 2014-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド N3-heteroaryl-substituted triazoles and N5-heteroaryl-substituted triazoles useful as Axl inhibitors
DK2114955T3 (en) 2006-12-29 2013-05-06 Rigel Pharmaceuticals Inc BRIDGED, BICYCLIC ARYL AND BRIDGED, BICYCLIC HETEROARYL SUBSITIATED TRIAZOLES USED AS AXL INHIBITORS
WO2009054864A1 (en) 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
RU2555326C2 (en) 2009-01-16 2015-07-10 Риджел Фармасьютикалз, Инк. Axl INHIBITORS APPLICABLE IN COMBINATION THERAPY FOR PREVENTING, RELIEVING OR TREATING METASTATIC CANCER
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
EP4132652A1 (en) 2020-04-08 2023-02-15 BerGenBio ASA Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy

Also Published As

Publication number Publication date
WO2023247769A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
IL290527A (en) Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
IL291452A (en) Dosage forms for tyk2 inhibitors
IL289949A (en) Dosing regimens for oral complement factor d inhibitors
IL283859A (en) Extended low dose regimens for mdm2 inhibitors
GB202004960D0 (en) Inhibitor compounds
IL290006A (en) A dosing regimen for an ido inhibitor
IL307188A (en) Nlrp3 inhibitors
GB202209285D0 (en) Dosage regimen for AXL inhibitor
GB202208131D0 (en) Dosage regimen for AXL inhibitor
IL310394A (en) Inhibitors for coronaviruses
IL309118A (en) Cdk2 inhibitors
EP4055061A4 (en) Dosage regimen for anti-egfrviii agents
GB202319534D0 (en) Dosage regimen
GB202306662D0 (en) Dosage regimen
GB202015771D0 (en) Dosage regimen
GB202014116D0 (en) Dosage regimen
GB202006819D0 (en) Dosage regimen
GB202006699D0 (en) Dosage regimen
IL308389A (en) Dosage regimens for ecubectedin
GB202215655D0 (en) Nuclear transport inhibitors for anti-cancer combination therapy
IL309246A (en) Dosing regimen for a tead inhibitor
IL310389A (en) Srpk inhibitors
GB202117224D0 (en) Inhibitor compounds
GB202307924D0 (en) Inhibitor compounds
GB202306601D0 (en) Inhibitor compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)